Abstract: A night vision device includes a binocular body in which is mounted, along an optical axis, an objective lens, a light intensifier tube, a light guide, and an eyepiece lens. The light intensifier tube includes a photocathode, a microchannel wafer, a phosphor screen intended to deliver a night vision image and a light guide having an input side contiguous to the phosphor screen and an output side intended to form an image in the focal plane of the eyepiece lens. The light intensifier tube further includes a display in the form of a thin glass plate or of a thin film comprising light-emitting elements, the thin plate/the thin film being directly arranged on the output side of the light guide. A power supply and control module, housed within the tube body, at the periphery of the light guide, delivers the respective bias voltages of the different elements of the light intensifier tube and controls the luminescence of the light-emitting elements of the display.

Abstract: A composition in the form of an injectable aqueous solution, for which the pH is comprised from 6.0 to 8.0, includes at least: a) amylin, an amylin receptor agonist or an amylin analogue; b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy, said co-polyamino acid being constituted of glutamic or aspartic units and said hydrophobic radicals Hy chosen according to formula X as defined below: c) characterized in that the composition does not include basal insulin for which the isoelectric point IP is comprised from 5.8 to 8.5. The composition also includes a prandial insulin.

Abstract: A composition in the form of an injectable aqueous solution, for which the pH is comprised from 6.0 to 8.0, includes at least: a) amylin, an amylin receptor agonist or an amylin analogue; b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy, said co-polyamino acid being constituted of glutamic or aspartic units and said hydrophobic radicals Hy chosen according to formula X as defined below: c) characterized in that the composition does not include basal insulin for which the isoelectric point IP is comprised from 5.8 to 8.5. The composition also includes a prandial insulin.

Abstract: The invention relates to solid composition comprising a peptide or a protein and an acylated aminoacid AC-aa, or a salt thereof, characterized in that: the acyl group-AC comprises from 4 to 9 carbon atoms, said composition comprises at least 300 mg/g of AC-aa relative to the total weight of the composition.

Abstract: An image intensifier device includes: an intensifier tube with at least one photocathode, a micro-channel plate and a conversion element, arranged in that order one after another, and an electric power supply module configured to supply at least one respective polarisation voltage to each of the elements of the intensifier tube. The electric power supply module extends in a region located upstream of the photocathode, on the side of the photocathode opposite to the micro-channel plate. Thus, a space is cleared located downstream of the intensifier tube in the direction of travel of the photons and of the electrons in the image intensifier device. This allows reducing the size of the image intensifier device for example by bringing an eyepiece closer.

Abstract: An image intensifier device includes: an intensifier tube with at least one photocathode, a micro-channel plate and a conversion element, arranged in that order one after another, and an electric power supply module configured to supply at least one respective polarisation voltage to each of the elements of the intensifier tube. The electric power supply module extends in a region located upstream of the photocathode, on the side of the photocathode opposite to the micro-channel plate. Thus, a space is cleared located downstream of the intensifier tube in the direction of travel of the photons and of the electrons in the image intensifier device. This allows reducing the size of the image intensifier device for example by bringing an eyepiece closer.

Abstract: A physically stable compositions in the form of an injectable aqueous solution with a pH from 6.0 to 8.0, include a basal insulin whose isoelectric point (pI) is from 5.8 to 8.5, and a co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical.

Abstract: A composition includes co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical -Hy that are chosen among the co-polyamino acids according to formula XXXb: wherein, D represents, independently, either a group —CH2— (aspartic acid) or a group —CH2—CH2— (glutamic acid), X represents a cationic entity chosen from the group comprising alkali cations, Rb and R?b, identical or different, are either a hydrophobic radical -Hy, or a radical chosen from the group consisting of an H, a C2 to C10 linear acyl group, a C3 to C10 branched acyl group, a benzyl, a terminal “amino acid” unit and a pyroglutamate, at least one of Rb and R?b is a hydrophobic radical -Hy, n+m represents the degree of polymerization DP of the co-polyamino acid, namely the mean number of monomeric units per co-polyamino acid chain and 5?n+m?250.

Abstract: The invention relates to a composition in the form of an injectable aqueous solution, wherein the pH is comprised from 6.0 to 8.0, comprising at least: a) amylin, an amylin receptor agonist or an amylin analog; b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy, characterized in that the composition does not comprise a basal insulin wherein the isoelectric point pI is comprised from 5.8 to 8.5. It also relates to a composition characterized in that it further comprises a prandial insulin.

Abstract: A physically stable composition in the form of an injectable aqueous solution, wherein the pH is from 6.0 to 8.0, including at least: a) a basal insulin which isoelectric point (pI) is from 5.8 and 8.5 and b) a copolyamino acid according to formula I: Q[Hy]j[PLG]k?? Formula I wherein: j?1; k?2.

Abstract: A composition in the form of an injectable aqueous solution, for which the pH is comprised from 6.0 to 8.0, includes at least: a) amylin, an amylin receptor agonist or an amylin analogue; b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy, said co-polyamino acid being constituted of glutamic or aspartic units and said hydrophobic radicals Hy chosen according to formula X as defined below: c) characterized in that the composition does not include basal insulin for which the isoelectric point IP is comprised from 5.8 to 8.5. The composition also includes a prandial insulin.

Abstract: Physically stable compositions in the form of an injectable aqueous solution, for which the pH is comprised from 6.0 to 8.0, having at least: human glucagon, and a co-polyamino acid bearing carboxylate charges and Hy hydrophobic radicals. In one embodiment, the compositions according to the invention also includes a gastro-intestinal hormone.

Abstract: Physically stable compositions in the form of an injectable aqueous solution, for which the pH is comprised from 6.0 to 8.0, having at least: human glucagon, and a co-polyamino acid bearing carboxylate charges and Hy hydrophobic radicals. In one embodiment, the compositions according to the invention also includes a gastro-intestinal hormone.

Abstract: A composition in the form of an injectable aqueous solution, wherein the pH is comprised from 6.0 to 8.0, includes at least: a) amylin, an amylin receptor agonist or an amylin analog; and b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy, wherein the composition does not comprise a basal insulin wherein the isoelectric point pI is comprised from 5.8 to 8.5. The composition may further include a prandial insulin.

Abstract: A composition in the form of an injectable aqueous solution, for which the pH is comprised from 6.0 to 8.0, includes at least: a) amylin, an amylin receptor agonist or an amylin analogue; b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy, said co-polyamino acid being constituted of glutamic or aspartic units and said hydrophobic radicals Hy chosen according to formula X as defined below: c) characterized in that the composition does not include basal insulin for which the isoelectric point IP is comprised from 5.8 to 8.5. The composition also includes a prandial insulin.

Abstract: Physically stable compositions in the form of an injectable aqueous solution, wherein the pH is from 6.0 to 8.0, includes at least: a) human glucagon and b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy. In one embodiment, the compositions further comprise a gut hormone.

Abstract: In an example implementation, a method includes illuminating a wafer with excitation light having a wavelength and intensity sufficient to induce photoluminescence in the wafer. The method also includes detecting photoluminescence emitted from a portion of the wafer in response to the illumination, and detecting excitation light reflected from the portion of the wafer. The method also includes comparing the photoluminescence emitted from the portion of the wafer and the excitation light reflected from the portion of the wafer, and identifying one or more defects in the wafer based on the comparison.

Abstract: A method for processing an acquired image (IA) showing a structured personal document (D) including a visual inspection zone (VIZ). The method includes determination of a first character string from an automatic reading zone or of barcode type (MRZ) of predetermined format, the first character string representing personalised information specific to the owner of the document (D), generation from the first character string of an intermediate image (IS) showing a second character string representing the same personalised information, detection in the acquired image of a third character string in the visual inspection zone (VIZ), representing the same personalised information, the detection comprising an overall comparison of the intermediate image (IS) with the acquired image, location in the visual inspection zone (VIZ) of a region of interest containing the third character string.

Abstract: A physically stable compositions in the form of an injectable aqueous solution with a pH from 6.0 to 8.0, include a basal insulin whose isoelectric point (pI) is from 5.8 to 8.5, and a co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical.

Abstract: In an example implementation, a method includes illuminating a wafer with excitation light having a wavelength and intensity sufficient to induce photoluminescence in the wafer. The method also includes detecting photoluminescence emitted from a portion of the wafer in response to the illumination, and detecting excitation light reflected from the portion of the wafer. The method also includes comparing the photoluminescence emitted from the portion of the wafer and the excitation light reflected from the portion of the wafer, and identifying one or more defects in the wafer based on the comparison.